EHA 2024 - Wrap-Up: Myelodysplastic Syndrome

At the 2024 European Hematology Association Annual Congress, researchers presented the multilineage and safety results from the COMMANDS trial of transfusion-dependent, erythropoiesis-stimulating agent–naïve patients with very low-, low-, or intermediate-risk myelodysplastic syndromes. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers analyzed the relationship between hemoglobin and the quality of life of transfusion-dependent patients with lower-risk myelodysplastic syndromes receiving luspatercept or epoetin alfa. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers presented the real-world dose escalation of luspatercept and its outcomes among patients with lower-risk myelodysplastic syndromes. Read More ›

At the European Hematology Association 2024 Annual Conference, researchers explored the emotional, physical, and financial burden experienced by patients with transfusion-dependent lower-risk myelodysplastic syndromes based in North America and Europe. Read More ›

Researchers presented a model to compare treatment outcomes for patients with lower-risk myelodysplastic syndromes who rely on red blood cell transfusions starting from first-line treatment initiation throughout their lifetime. Read More ›